RxTrials Institute Drug Pipeline Alert
March 12, 2008 | Vol. 6 No. 11
Renal Cancer Trial to Begin
UK drugmaker Oxford BioMedica has completed patient enrollment in the Phase III study of TroVax in renal cancer.
The randomized, placebo-controlled, two-arm TRIST study evaluated TroVax in combination with standard-of-care. The company expects to complete final analysis in the first half of 2009.
Sanofi-aventis, Oxford’s TroVax partner, will start a Phase III trial of the therapy in colorectal cancer, according to Mike McDonald, Oxford’s chief medical officer.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.